Minimal Residual Disease Persistence
1 clinical trials · Condition
◉ Watch Minimal Residual Disease Persistence
| Record | Firm | Date |
|---|---|---|
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission (NCT04062266) | M.D. Anderson Cancer Center | 2019-09-13 |
Track Minimal Residual Disease Persistence automatically
Every clearance here is in the API, with alerts when new ones post.